[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100449332":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants receiving Somavert",null,[12],"Drug: Somavert",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Somavert","As provided in real world practice",[9],[20],{"name":21,"affiliation":5,"role":22},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[29],{"facility":5,"status":30,"city":31,"state":10,"zip":32,"country":33,"countryCode":10,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"RECRUITING","Seoul","01037","South Korea",{"type":35,"coordinates":36},"Point",[37,38],126.9784,37.566,{"lat":38,"lon":37},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100449332","korean-regulatory-post-marketing-surveillance-for-somavert-100449332",false,"NCT05131100","Korean Regulatory Post Marketing Surveillance for Somavert","Korean Post-marketing Surveillance for Somavert","Inclusion Criteria:\n\nAll patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible.\n\nExclusion Criteria:\n\nPatients who are contraindicated for Somavert","ALL","18 Years",{"count":52,"type":53},100,"ESTIMATED","OBSERVATIONAL","Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)",[57],"Acromegaly",[59],"acromegaly, Somavert, Post-Marketing Surveillance","2025-07-02",{"date":62,"type":63},"2025-07-04","ACTUAL",{"date":65,"type":63},"2022-07-13",{"date":67,"type":53},"2026-09-15",{"name":5,"class":6},1]